Agenus Announced Sunday, Phase 2 NEOASIS Data At ESMO Showing 72% Of Locally Advanced dMMR Colon Cancer Patients Had No Cancer Remaining At Surgery After 6 Weeks Of BOT+BAL; 83% Achieved Major Pathologic Response, Meeting Primary Endpoint

Loading news article.

Agenus Announced Sunday, Phase 2 NEOASIS Data At ESMO Showing 72% Of Locally Advanced dMMR Colon Cancer Patients Had No Cancer Remaining At Surgery After 6 Weeks Of BOT+BAL; 83% Achieved Major Pathologic Response, Meeting Primary Endpoint | WAPE

Agenus Announced Sunday, Phase 2 NEOASIS Data At ESMO Showing 72% Of Locally Advanced dMMR Colon Cancer Patients Had No Cancer Remaining At Surgery After 6 Weeks Of BOT+BAL; 83% Achieved Major Pathologic Response, Meeting Primary Endpoint

Article summary

Related companies

Comments —